Lyell reports Q1 net loss $60.7M; cash $526.3M; LYL797 data due this quarter

Lyell Immunopharma, Inc.

2024-Q1 EPS reported -$0.24 revenue$3,000

Net loss $60.7M vs $67.0M YoY; non-GAAP net loss $37.5M vs $44.8M.
Cash, equivalents and securities $526.3M; expected to fund operations into 2027.
Initial Phase 1 data for LYL797 (ROR1 CAR T) expected this quarter from ≥20 patients.
LYL845 (TIL) Phase 1 data expected H2 2024; LYL119 IND submission expected this quarter.
R&D expenses $43.2M vs $44.6M; G&A $13.5M vs $19.3M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyell Immunopharma, Inc. reported the quarter ended March 31, 2024 results: net income net loss of $60.7 million.

Period: the quarter ended March 31, 2024
Net income: net loss of $60.7 million
Result: reported results

Exact text from the filing

On May 6, 2024, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lyell Immunopharma, Inc. reported the first quarter ended March 31, 2024 results: net income net loss of $60.7 million.

Period: the first quarter ended March 31, 2024
Net income: net loss of $60.7 million
Result: reported results

Exact text from the filing

Lyell reported a net loss of $60.7 million for the first quarter ended March 31, 2024, compared to a net loss of $67.0 million for the same period in 2023.

View on SEC.gov

710 earnings releases filed in the last 30 days. Browse all earnings releases →

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-020466

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.